Lilial SAS
Next-day home delivery of medical products for patients.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
$42.8m Valuation: $42.8m 1.1x EV/Revenue 12.1x EV/EBITDA | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 21 % | 14 % | (18 %) | 34 % | - | 10 % | 11 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 11 % | 9 % | 7 % | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 7 % | 6 % | 4 % | - | (5 %) | (1 %) | (3 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Lilial SAS operates as a specialized direct-to-consumer home delivery company within the French healthcare sector, focusing on medical supplies for chronic conditions. The company was founded in 2003 by Denis Marliac, whose personal experience as a tetraplegic following an accident directly inspired the company's mission. His ambition was to address the daily needs for freedom, privacy, and well-being for individuals requiring medical devices at home.
The firm's core business involves the nationwide distribution of medical products for patients with urinary incontinence, ostomy care needs, and wound care requirements. Lilial functions as a crucial link between the hospital and the patient's home, aiming to facilitate a smooth transition and help individuals better manage their medical equipment daily. The business model is centered on providing personalized service and logistical support. It delivers devices from a range of manufacturers, ensuring patients have access to necessary supplies without being limited to a single brand. This multi-brand approach is a key part of its service offering. The client base consists of patients in France who require ongoing care for intimate and chronic disorders.
A significant milestone in Lilial's history was its acquisition by Coloplast A/S in December 2017 for a cash consideration of €35.5 million. At the time of the acquisition, Lilial had approximately 80 employees and was projected to achieve sales of around €33 million for 2017. The acquisition was part of Coloplast's strategy to enhance its service offerings and strengthen its market position in France. Despite the acquisition, Lilial continues to operate as a distinct entity and a subsidiary of Coloplast, maintaining neutrality with its various partners. Keywords: medical device delivery, home healthcare France, ostomy supplies, catheter supplies, wound care products, direct-to-consumer healthcare, patient home delivery, chronic care solutions, medical logistics, incontinence products, Coloplast subsidiary, healthcare services, medical equipment distribution, post-hospital care, personalized patient support, Denis Marliac, French medtech, healthcare supply chain, urology supplies, stomatherapy